endocrine:glp1:semaglutide
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| endocrine:glp1:semaglutide [2026/02/13 00:16] – [GLP-1 vs SGLT2 in Cardiovascular Disease] andrew2393cns | endocrine:glp1:semaglutide [2026/02/13 00:17] (current) – [Clinical Pearls] andrew2393cns | ||
|---|---|---|---|
| Line 167: | Line 167: | ||
| ===== Clinical Pearls ===== | ===== Clinical Pearls ===== | ||
| - | ✔ Weekly or oral option | + | * ✔ Weekly or oral option |
| - | ✔ Powerful weight loss | + | |
| - | ✔ Reduces ASCVD events | + | |
| - | ✔ Low hypoglycemia risk | + | |
| - | ✔ Not a core heart failure therapy | + | |
| - | ✔ Monitor for GI intolerance | + | |
| -------------------------------------------------------------------- | -------------------------------------------------------------------- | ||
endocrine/glp1/semaglutide.1770941812.txt.gz · Last modified: by andrew2393cns
